Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
8/4 01:45
Company Announcement COPENHAGEN , Denmark; April 8 , 2022 – Genmab A/S (Nasdaq: GMAB) announced today an award in the binding arbitration of two matters arising under its license agreement with Janssen Biotech, Inc. (Janssen) relating to daratumumab. The arbitral tribunal issued an award on April...